X4 Pharmaceuticals (XFOR) Total Current Liabilities (2017 - 2026)

X4 Pharmaceuticals (XFOR) has reported Total Current Liabilities for 10 consecutive years, with $19.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 15.42% year-over-year to $19.4 million; the trailing twelve-month figure through Jun 2026 stood at $19.4 million (down 15.42% YoY), and the FY2025 full-year result was $25.8 million, down 21.66% from the prior year.
• Total Current Liabilities eased to $19.4 million in Q2 2026 per XFOR's latest filing, from $23.8 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $32.9 million in Q4 2024 and bottomed at $15.0 million in Q1 2022.
• Historically, Total Current Liabilities has averaged $24.1 million across 5 years, with a median of $23.5 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities jumped 117.0% in 2022, then fell 21.66% in 2025.
• Over 5 years, Total Current Liabilities stood at $22.3 million in 2022, then advanced by 2.41% to $22.9 million in 2023, then soared by 43.81% to $32.9 million in 2024, then dropped by 21.66% to $25.8 million in 2025, then decreased by 24.81% to $19.4 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $19.4 million, $23.8 million, and $25.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.